BASF's Agribusiness IPO Prep and Buyback Push Converge as Chemicals Giant Recasts Its Balance Sheet

BASF accelerates €4B buyback, repays €1.6B debt, and preps agribusiness IPO for 2027, while raising chemical prices in North America and Europe.

The chemicals group is running two parallel tracks that are reshaping how investors value the company: readying its crop-science division for a standalone stock-market debut while simultaneously funneling capital back to shareholders. That dual strategy is now visible in daily operations, from a freshly opened Mumbai laboratory to the steady repurchase of the company's own equity.

On the buyback front, BASF disclosed that it acquired 695,000 of its own shares between August 10 and 14, bringing the cumulative total since the program's August 3 launch to 1.24 million shares. The current tranche, capped at €1 billion, runs through the end of April 2027 and forms part of a broader €4 billion repurchase scheme announced in September 2024 that extends to the close of 2028. Between November 2025 and June 2026, the company had already retired roughly €1.5 billion worth of stock, canceling about 31.6 million shares — equivalent to approximately 3.5 percent of its share capital.

The capital-return effort is matched by a parallel push to lighten the liability side of the ledger. BASF plans to redeem bonds and loans with a combined nominal volume of €1.6 billion in the third quarter, an early-debt-repayment move that dovetails with the buyback to produce a leaner, more capital-efficient structure.

Meanwhile, the groundwork for the agribusiness spin-off is accelerating. The division, BASF Agricultural Solutions, has been making tangible operational strides: a new Climate Center at Limburgerhof received an investment in the low double-digit millions on August 12, and the second generation of the xarvio CONNECT digital platform — a wearable device that syncs field-management software with machinery terminals — has been live in North America since August 13. On Wednesday, the group opened a performance lab in Mumbai dedicated to diapers and superabsorbents.

These moves feed into a larger ambition. The agribusiness IPO is slated for 2027, and media reports have floated a valuation range of €20 billion to €30 billion for the division — a figure that would represent a substantial contribution relative to BASF's current total market capitalization of €44.04 billion. Timing and final sizing, according to those reports, will hinge on market conditions. If realized at the upper end of that range, the listing could rank among Europe's largest public offerings in a decade.

Pricing power is also being deployed across multiple product lines. In North America, the company is raising prices for caprolactam, polyamide 6 and copolyamide by $0.08 per pound, effective September 1 or as contracts allow. Neopentyl glycol prices in the U.S. and Canada were hiked by $0.10 per pound — or $221 per ton — on August 13, following a European increase a day earlier that added €250 per ton for neopentyl glycol and €300 per ton for 1,6-hexanediol, effective immediately or per contract terms. These increases target basic chemicals used in plastics, coatings and fibers, signaling that BASF intends to pass along higher raw-material and energy costs rather than absorb them through efficiency measures alone.

The market has taken notice. The share price advanced 1.8 percent on Wednesday to €51.90, following a prior close of €51.00. That puts the stock up 17 percent since the start of the year and 5.6 percent above its 50-day moving average of €49.14. The gap to the 52-week high of €55.05, set on April 14, now stands at 5.7 percent — though the secondary article pegs the distance at 7.4 percent, a discrepancy that reflects the timing of the respective observations. Over the 30-day window, the stock has gained 6.5 percent.

Beyond the financial engineering, BASF continues to invest in infrastructure and innovation. In Ludwigshafen, ground was broken Monday on a modernization of the combined-transport terminal, an event attended by political and business figures. In personal care, the company introduced Floragenist, a new generation of floral active ingredients.

For investors, the converging narratives — a potential blockbuster agribusiness listing, disciplined capital returns and broad-based price increases — paint a picture of a conglomerate in active transformation. The question that will ultimately be settled in 2027 is what the market decides the standalone crop-science business is actually worth.